| Product Unit Size | Cost | Quantity | Stock |
|---|
Spiramycin is a macrolide antibiotic that is clinically used to treat toxoplasmosis and other soft tissue infections. Spiramycin exhibits antibacterial efficacy against Toxoplasma, inhibiting bacterial protein synthesis. In vitro, spiramycin decreases levels of IL-10 and TNF-α, and in vivo, it decreases Toxoplasma-induced brain cysts.
| Cas No. | 11034-40-5 |
|---|---|
| Purity | ≥90% |
| Synonym | Spiramycin Adipate, stomamycin, suanovil |
| Solubility | Soluble in most organic solvents. |
| Appearance | Slightly yellowish or white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Calcagnile M, Jeguirim I, Tredici S, et al. Spiramycin disarms Pseudomonas aeruginosa without inhibiting growth. Antibiotics (Basel). 2023 Mar 2;12(3):499. PMID: 36978366.
Kang J, Kang H, Hyun C. Anti-inflammatory effects of spiramycin in LPS-activated RAW 264.7 macrophages. Molecules. 2022 May 17;27(10):3202. PMID: 35630676.
Omar M, Abaza B, Mousa E, et al. Effect of spiramycin versus aminoguanidine and their combined use in experimental toxoplasmosis. J Parasit Dis. 2021 Dec;45(4):1014-1025. PMID: 34789985.
Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol. 2013;112:1099-101. PMID: 23622316.
Büyükbaba Boral O, Sönmez Tamer G, Keçeli Özcan S, et al. Investigation of combined effectiveness of spiramycin and beta-glucan in mice models of acute toxoplasmosis and determination of IL-10, IL-12 and TNF-α levels. Mikrobiyol Bul. 2012 Jul;46(3):446-55. PMID: 22951656.
Chew WK, Segarra I, Ambu S, et al. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1762-8. PMID: 22271863.